In a separate 2023 statement from 18 gastroenterology associations in the European Economic Area, 14 (77.8%) endorsed initiating anti-TNF-α therapy with a biosimilar for the treatment of IBD [57]. The gene discussed is TNF; the disease is inflammatory bowel disease.